secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2026-07-07T20:38:54+00:00
Accession:  0001193125-26-297554
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharmaceuticals appoints Donn Casale as CEO, replacing Richard Lowenthal terminated without cause
--------------------------------------------------------------------------------

- Donn Casale, previously President, appointed CEO effective July 7, 2026.
- Richard Lowenthal terminated without cause on July 6, 2026.
- Casale also appointed to Board as Class III director until 2029 annual meeting.
- No details on compensation or transition provided in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/0001193125-26-297554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526297554/d157645d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-297554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer